Antibody Therapeutics Targeting Aβ and Tau

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Active and passive immunization against amyloid-beta (Aβ) in Alzheimer's disease (AD) mouse models reduced amyloid burden, spurring clinical trials.
• Clinical trials faced challenges with methodology and adverse effects, necessitating safer immunotherapeutic strategies for AD.
• Emerging research identifies tau as a potential immunotherapeutic target for tauopathies like frontotemporal lobar dementia (FTLD).

Purpose of the Study:

• To review the development of immunotherapies targeting amyloid-beta (Aβ) for Alzheimer's disease (AD).
• To explore the potential of tau as an alternative immunotherapeutic target for neurodegenerative diseases.
• To highlight advancements in preclinical models and the anticipation of future clinical trials.

Main Methods:

• Review of preclinical studies involving active and passive immunization strategies against Aβ and tau in mouse models.
• Analysis of clinical trial outcomes and challenges associated with Aβ-targeting immunotherapies.
• Evaluation of cognitive performance and pathological markers in response to tau-targeting immunotherapies.

Main Results:

• Immunization against Aβ in mouse models demonstrated significant reduction in amyloid burden.
• Tau immunization in mouse models of tauopathy effectively reduced tau pathology and improved cognitive function.
• Preclinical success suggests tau as a viable alternative target for neurodegenerative disease treatment.

Conclusions:

• Despite initial challenges, Aβ immunotherapy remains an area of active research with a focus on safety and efficacy.
• Tau immunotherapy presents a promising alternative for treating tauopathies and potentially other neurodegenerative conditions.
• Further clinical trials are anticipated for both Aβ and tau-based immunotherapies to address cognitive decline.